Page 208 - Read Online

Zhao et al. Hepatoma Res 2019;5:17 I http://dx.doi.org/10.20517/2394-5079.2018.116 Page 9 of 10

Availability of data and materials
Not applicable.

Financial support and sponsorship
This study was funded by the National Natural Science Foundations of China (81773488, 81172287).

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
The Authors 2019.

REFERENCES
1. Wen T, Jin C, Facciorusso A, Donadon M. Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after
resection: an international expert consensus. Hepatobiliary Surg Nutr 2018;7:353-71.
2. Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma.
Gastroenterology 2016;150:835-53.
3. Hsiang JC, Wong GL, Tse YK. Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected
population: a propensity score landmark analysis. J Hepatol 2015;63:1190-7.
4. Minocha J, Salem R, Lewandowski RJ. Transarterial chemoembolization and yttrium-90 for liver cancer and other lesions. Clin Liver
Dis 2014;18:877-90.
5. Xu J, Noda C, Erickson A, Mokkarala M, Charalel R, et al. Radiofrequency ablation vs. cryoablation for localized hepatocellular
carcinoma: a propensity-matched population study. Anticancer Res 2018;38:6381-6.
6. Vogl TJ, Nour-Eldin NA, Hammerstingl RM, Panahi B. Microwave ablation (MWA): basics, technique and results in primary and
metastatic liver neoplasms-review article. Rofo 2017;189:1055-66.
7. Yang Z, Chen G, Cui Y. The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma:
a retrospective study. Cancer Biol Ther 2019;20:321-7.
8. Zhao M, Wang JP, Wu PH, Zhang FJ, Huang ZL, et al. Comparative analysis of TACE alone or plus RFA in the treatment of 167 cases
of intermediate and advanced staged primary hepatocellular carcinoma. Zhonghua Yi Xue Za Zhi 2010;90:2916-21. (in Chinese)
9. Sato Y, Nishiofuku H, Yasumoto T, Nakatsuka A, Matsuo K. Multicenter phase II clinical trial of sorafenib combined with transarterial
chemoembolization for advanced stage hepatocellular carcinomas (Barcelona clinic liver cancer stage C): STAB study. J Vasc Interv
Radiol 2018;29:1061-7.
10. Wada Y, Takami Y, Matsushima H. The safety and efficacy of combination therapy of sorafenib and radiotherapy for advanced
hepatocellular carcinoma: a retrospective study. Intern Med 2018;57:1345-53.
11. Meng M, Wang H, Zeng X, Zhao L, Yuan Z. Stereotactic body radiation therapy: A novel treatment modality for inoperable hepatocellular
carcinoma. Drug Discov Ther 2015;9:372-9.
12. Higgins JP1, Altman DG. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
13. Ikeda M, Morizane C. Chemotherapy for hepatocellular carcinoma: current status and future perspectives. Jpn J Clin Oncol
2018;48:103-14.
14. Ikeda M, Mitsunaga S. Systemic chemotherapy for advanced hepatocellular carcinoma: past, present, and future. Diseases 2015;3:360-81.
15. Han Z, He Z, Wang C, Wang Q. The effect of apatinib in the treatment of sorafenib resistant metastatic hepatocellular carcinoma: a case
report. Medicine (Baltimore) 2018;97:e13388.
16. Raoul JL, Forner A, Bolondi L, Cheung TT, Kloeckner R, et al. Updated use of TACE for hepatocellular carcinoma treatment: how and
when to use it based on clinical evidence. Cancer Treat Rev 2018;72:28-36.
17. Yao E, Chen J. Efficacy of stereotactic body radiotherapy for recurrent or residual hepatocellular carcinoma after transcatheter arterial
chemoembolization. Biomed Res Int 2018;2018:54881909.
18. Hehr T, Budach W, Lamprecht U. Experimental thermoradiotherapy in malignant hepatocellular carcinoma. Int J Radiat Oncol Biol
Phys 2003;55:1374-80.
19. Honda Y, Kimura T, Aikata H. Stereotactic body radiation therapy combined with transcatheter arterialchemoembolization for small